Journal Article

Mycobacterial and Other Serious Infections in Patients Receiving Anti-Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

Kevin L. Winthrop, S. Yamashita, S. E. Beekmann and P. M. Polgreen

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 46, issue 11, pages 1738-1740
Published in print June 2008 | ISSN: 1058-4838
Published online June 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/587989
Mycobacterial and Other Serious Infections in Patients Receiving Anti-Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti—tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

Journal Article.  2078 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.